

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

UROGEN PHARMA LTD., and UROGEN
PHARMA, INC.,

Plaintiffs,

v.

TEVA PHARMACEUTICALS, INC.,
TEVA PHARMACEUTICALS USA, INC.,
and TEVA PHARMACEUTICAL
INDUSTRIES LTD.

Defendants.

Civil Action No. _____

**SUPPLEMENTAL INFORMATION FOR PATENT CASES
INVOLVING AN ABBREVIATED NEW DRUG APPLICATION (ANDA)**

Plaintiffs hereby provide the information below with respect to the deadlines set forth in 21 U.S.C. 355(j):

Date Patentee(s) Received Notice: February 25, 2024

Date of Expiration of Patents: January 20, 2031

Stay Deadline: No earlier than April 15, 2027¹

¹ Current expiration of Orphan Drug Exclusivity.

Dated: April 2, 2024

McCARTER & ENGLISH, LLP

OF COUNSEL:

William E. Solander
Daniel J. Minion
Katherine E. Adams
Justin M. Dersh
Philip J. Dutko
VENABLE LLP
151 West 42nd Street, 49th Floor
New York, NY 10036
(212) 307-5500

/s/ Daniel M. Silver

Daniel M. Silver (#4758)
Alexandra M. Joyce (#6423)
Renaissance Centre
405 N. King St., 8th Floor
Wilmington, DE 19801
(302) 984-6300
dsilver@mccarter.com
ajoyce@mccarter.com

Attorneys for Plaintiffs

Evan S. Krygowski
VENABLE LLP
600 Massachusetts Ave., NW
Washington, DC 20001
(202) 344-4000